Regardless of neonatal lung disease status, infants born before 29 weeks' gestation demonstrated abnormal pulmonary artery acceleration time at 1-year corrected age.
In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.
A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.
Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.
Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.
N-terminal-pro brain natriuretic peptide may be a useful biomarker for both mortality and respiratory exacerbations in pediatric patients with pulmonary hypertension.
Patients with pulmonary hypertension have a high risk for adverse events during and following cardiac catheterization, but high case volume may help ameliorate this risk.
The hemodynamic parameters predict mortality and cardiac hospitalization in patients with heart failure with preserved ejection fraction.
A 57-year-old woman has been experiencing progressive exertional dyspnea during the past 6 months as well as a near syncopal episode while attempting to catch a taxi.
Hemodynamic markers of pulmonary hypertension in heart failure with preserved ejection fraction are associated with mortality
Transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient are predictors of mortality and cardiac hospitalizations in pulmonary hypertension associated with heart failure with preserved ejection fraction.
Several months after being diagnosed with pulmonary arterial hypertension, a 32-year-old pregnant woman presents with worsening dyspnea.
Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions for US veterans are inconsistent with pulmonary hypertension guidelines.
Patients with pulmonary arterial hypertension may be better identified through a claims-based algorithm that includes ICD-9-CM codes, specific pulmonary arterial hypertension medications, echocardiography, and right heart catheterization.
Women with pulmonary arterial hypertension experienced better long-term prognosis than men with PAH.
Enlargement of the right atrium is associated with an increased risk for supraventricular arrhythmias in PAH.
Varicose veins may increase the risk for pulmonary embolism and peripheral artery disease.
Peak circulatory power offers greater value than peak oxygen uptake and ventilation in predicting cardiac events in patients with idiopathic PAH.
Hypoxemia in individuals with idiopathic PAH is associated with increased mortality risk.
Observation in the emergency department followed by outpatient management with anticoagulation may be appropriate treatment for some patients with low-risk pulmonary embolism.
In patients at very low risk for pulmonary embolism, the pulmonary embolism rule-out criteria was noninferior to the conventional strategy of identifying thromboembolic events.
Pulmonary Embolism Rule-out Criteria non-inferior to usual care for patients at low-risk for pulmonary embolism
In this multicenter, randomized controlled study, the Pulmonary Embolism Rule-out Criteria (PERC) strategy resulted in significantly fewer uses of CT pulmonary angiography, reduced ED length of stay, and fewer hospital admissions.
Based on this retrospective cohort study from multiple countries, the prevalence of pulmonary embolism in patients presenting to the emergency department with syncope was low.
Patients with suspected PH should undergo two 6MWTs to improve the accuracy of exercise capacity measurements.
The 6-minute walk test had prognostic value with respect to mortality in a population of patients with pulmonary arterial hypertension.
Individuals treated with riociguat for pulmonary hypertension may have a greater risk for gastrointestinal disorders compared with tadalafil and sildenafil.
Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.
Thyroid hormone supplementation may be a promising treatment for idiopathic pulmonary fibrosis [PreClinical]
An enzyme involved in thyroid hormone activation was found to be elevated in patients with pulmonary fibrosis.
Although the Wells and revised Geneva scores are used in the general population to predict pulmonary embolism, researchers found they were not reliable in pregnant and postpartum women.
Pulmonary hemodynamic changes in chronic thromboembolic pulmonary hypertension may be monitored via the 6-minute walk test.
Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.
A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.
The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.
A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.
Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.
A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.
Prospective validation research is needed before these clinical predictors of pediatric PE can become guidelines.
A systematic review evaluated whether catheter-directed thrombolysis improved outcomes in patients with intermediate-risk pulmonary emboli.
The use of veno-arterial extracorporeal membrane oxygenation as bridge therapy for massive pulmonary embolism may allow clinicians to better triage patients to appropriate destination therapy.
Individuals who are HIV-positive may be at a higher risk for increased pulmonary pressure and mortality.
A study evaluated the quality of targeted anticoagulation in patients with PAH, and examined outcomes associated with poor time spent within targeted anticoagulation range.
Lung transplantation may be an option in patients with severe pulmonary arterial hypertension who do not respond well to medical therapy.
Select pediatric patients with pulmonary arterial hypertension may benefit from treatment with riociguat.
A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.
Hemodynamics may improve in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty with complication rates comparable to pulmonary endarterectomy.
Study results confirm the benefits of exercise vs granulocyte-macrophage colony-stimulating factor in improving 6-minute walk test in PAD.
Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.
Pulmonary and thoracic symptoms often coincide with initial presentation of connective tissue disease.
Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.
Results show statistically significant differences between SSc-PAH groups and iPAH groups for variables including age, sex, FVC capacity, total lung capacity, and FEV1, among others.
Patients with pulmonary arterial hypertension have reduced cerebrovascular reactivity to CO2.
Respiratory muscle dysfunction, iron deficiency, and skeletal muscle dysfunction have been implicated as mechanisms for exercise intolerance in pulmonary arterial hypertension.
The new device features a more ergonomic design with a single-button operation, an intuitive user interface to adjust breath counts, a rechargeable battery, and a display that guides patients through the inhalation process.
The frequency of eukaryotic translation initiation factor 2 alpha kinase 4 gene (EIF2AK4) mutations in patients with pulmonary arterial hypertension was investigated.
Borderline PH was linked to increased mortality after adjustment for 34 variables.
Patients who develop pulmonary edema after starting prostacyclin for pulmonary arterial hypertension have a greater risk for mortality.
Pulmonary vascular compliance may independently predict survival and prognosis in patients with pulmonary arterial hypertension associated with congenital heart disease.
Patients with pulmonary arterial hypertension experienced better improvements in pulmonary arterial compliance with riociguat compared with phosphodiesterase type 5 inhibitors.
Lung disease experts Athol Wells, MD, and Joshua Mooney, MD, MS, debate the diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis.
Right ventricular epicardial vasculature is more extensive in patients with pulmonary arterial hypertension compared with individuals without disease.
Results indicate that further study of the relationship between the 6-minute walk distance test and functional capacity in PAH is necessary.
A study sought to describe the occurrence of different types of pulmonary hypertension in hereditary hemorrhagic telangiectasia.
Depression, anxiety, and reduced healthcare-related quality of life are common in patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
A 65-year-old man with COPD presents with worsening exertional dyspnea.
Methamphetamine-associated pulmonary arterial hypertension has a higher risk for clinical worsening compared with idiopathic pulmonary arterial hypertension.
Having at least 2 features of pulmonary veno-occlusive disease demonstrated a trend toward worse survival in patients with pulmonary arterial hypertension and systemic sclerosis.
Specific guidelines should be developed for the use of the 6-minute walk test in idiopathic pulmonary fibrosis.
Pulmonary arterial hypertension tends to vary in presentation in patients of different races and ethnicities.
Differences in right ventricular morphology may predict the hemodynamic nature of pulmonary hypertension.
Pulmonary endarterectomy is an effective and durable treatment for chronic thromboembolic pulmonary hypertension.
Prenatal factors such as intrauterine growth retardation, infection, and placental inflammation can affect lung development in neonates.
Influenza vaccination does not increase the risk for venous thromboembolism in patients older than 50 years of age.
Similar short-term outcomes were seen in patients with saddle and nonsaddle pulmonary embolism.
Patients undergoing pulmonary vasodilatory therapy were more functional at initial presentation.
The guidelines for PAD were updated.
Poor outcomes in pulmonary arterial hypertension may be linked to worsening right atrial function.
Charleston comorbidity index is an independent predictor of mortality in patients with hemodynamically stable pulmonary embolism.
Most patients with sarcoidosis have a good prognosis, but age, extensive fibrosis, and pulmonary hypertension are associated with an increase in mortality.
Researchers were able to successfully use a fully implantable delivery system for treprostinil for adult patients with pulmonary arterial hypertension.
A retrospective analysis demonstrated that the ratio of left to right ventricular end-diastolic pressures can predict outcomes in patients with PH.
New criteria by the American College of Radiology detail appropriateness of various imaging techniques for suspected pulmonary hypertension.
Data from 150 patients suggested that lung diffusion capacity is the most relevant predictive factor for reduced 6-minute walk distance in SAPH.
Study results suggest that gas trapping, not emphysema, is associated with pulmonary vascular remodeling in COPD.